JPH0226958B2 - - Google Patents
Info
- Publication number
- JPH0226958B2 JPH0226958B2 JP55047096A JP4709680A JPH0226958B2 JP H0226958 B2 JPH0226958 B2 JP H0226958B2 JP 55047096 A JP55047096 A JP 55047096A JP 4709680 A JP4709680 A JP 4709680A JP H0226958 B2 JPH0226958 B2 JP H0226958B2
- Authority
- JP
- Japan
- Prior art keywords
- diphosphate
- present
- oligoribonucleotides
- papa
- reaction
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000001177 diphosphate Substances 0.000 claims description 10
- 239000003054 catalyst Substances 0.000 claims description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 108091028664 Ribonucleotide Proteins 0.000 claims description 3
- 125000000217 alkyl group Chemical group 0.000 claims description 3
- 239000002336 ribonucleotide Substances 0.000 claims description 3
- 125000002652 ribonucleotide group Chemical group 0.000 claims description 3
- 229910019142 PO4 Inorganic materials 0.000 claims description 2
- 239000010452 phosphate Substances 0.000 claims description 2
- 238000006243 chemical reaction Methods 0.000 description 6
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 4
- 101710086015 RNA ligase Proteins 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 description 2
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 241001442654 Percnon planissimum Species 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 229920005654 Sephadex Polymers 0.000 description 2
- 239000012507 Sephadex™ Substances 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 229910001629 magnesium chloride Inorganic materials 0.000 description 2
- 150000004702 methyl esters Chemical class 0.000 description 2
- 238000001243 protein synthesis Methods 0.000 description 2
- 230000014616 translation Effects 0.000 description 2
- UHDGCWIWMRVCDJ-UHFFFAOYSA-N 1-beta-D-Xylofuranosyl-NH-Cytosine Natural products O=C1N=C(N)C=CN1C1C(O)C(O)C(CO)O1 UHDGCWIWMRVCDJ-UHFFFAOYSA-N 0.000 description 1
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
- 125000001572 5'-adenylyl group Chemical group C=12N=C([H])N=C(N([H])[H])C=1N=C([H])N2[C@@]1([H])[C@@](O[H])([H])[C@@](O[H])([H])[C@](C(OP(=O)(O[H])[*])([H])[H])([H])O1 0.000 description 1
- 108091027075 5S-rRNA precursor Proteins 0.000 description 1
- ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 description 1
- 229910000013 Ammonium bicarbonate Inorganic materials 0.000 description 1
- 241000255789 Bombyx mori Species 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- UHDGCWIWMRVCDJ-PSQAKQOGSA-N Cytidine Natural products O=C1N=C(N)C=CN1[C@@H]1[C@@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-PSQAKQOGSA-N 0.000 description 1
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- XCCTYIAWTASOJW-UHFFFAOYSA-N UDP-Glc Natural products OC1C(O)C(COP(O)(=O)OP(O)(O)=O)OC1N1C(=O)NC(=O)C=C1 XCCTYIAWTASOJW-UHFFFAOYSA-N 0.000 description 1
- XCCTYIAWTASOJW-XVFCMESISA-N Uridine-5'-Diphosphate Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(=O)OP(O)(O)=O)O[C@H]1N1C(=O)NC(=O)C=C1 XCCTYIAWTASOJW-XVFCMESISA-N 0.000 description 1
- XYVNHPYNSPGYLI-UUOKFMHZSA-N [(2r,3s,4r,5r)-5-(2-amino-6-oxo-3h-purin-9-yl)-4-hydroxy-2-(phosphonooxymethyl)oxolan-3-yl] dihydrogen phosphate Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](OP(O)(O)=O)[C@H]1O XYVNHPYNSPGYLI-UUOKFMHZSA-N 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 235000012538 ammonium bicarbonate Nutrition 0.000 description 1
- 239000001099 ammonium carbonate Substances 0.000 description 1
- 238000012870 ammonium sulfate precipitation Methods 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- UHDGCWIWMRVCDJ-ZAKLUEHWSA-N cytidine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-ZAKLUEHWSA-N 0.000 description 1
- 125000002740 cytidyl group Chemical group 0.000 description 1
- XQRLCLUYWUNEEH-UHFFFAOYSA-L diphosphonate(2-) Chemical compound [O-]P(=O)OP([O-])=O XQRLCLUYWUNEEH-UHFFFAOYSA-L 0.000 description 1
- MWEQTWJABOLLOS-UHFFFAOYSA-L disodium;[[[5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-oxidophosphoryl] hydrogen phosphate;trihydrate Chemical compound O.O.O.[Na+].[Na+].C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP([O-])(=O)OP(O)([O-])=O)C(O)C1O MWEQTWJABOLLOS-UHFFFAOYSA-L 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- GTUJJVSZIHQLHA-XPWFQUROSA-N pApA Chemical compound C1=NC2=C(N)N=CN=C2N1[C@@H]([C@@H]1O)O[C@H](COP(O)(O)=O)[C@H]1OP(O)(=O)OC[C@H]([C@@H](O)[C@H]1O)O[C@H]1N1C(N=CN=C2N)=C2N=C1 GTUJJVSZIHQLHA-XPWFQUROSA-N 0.000 description 1
- -1 pApA pyridinium salt Chemical class 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
Landscapes
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Description
【発明の詳細な説明】
本発明はオリゴリボヌクレオチドの製造法に関
する。さらに詳しくは、アール・エヌ・エーリガ
ーゼを触媒として用いるオリゴリボヌクレオチド
の製造法に関する。DETAILED DESCRIPTION OF THE INVENTION The present invention relates to a method for producing oligoribonucleotides. More specifically, the present invention relates to a method for producing oligoribonucleotides using RN eligase as a catalyst.
近来、核酸が生体の重要な機能である遺伝形質
の伝達や蛋白質合成などに果している役割が解明
されるにおよんで、その構造と機能の関連性をよ
り深く知ることがますます重要になつてきてい
る。そして所望の塩基配列を有するオリゴヌクレ
オチドを合成し、蛋白合成系に与える影響を調べ
ることによつて、構造と機能の関連を知ることも
１つの研究方法としてよくおこなわれている。 In recent years, as the role that nucleic acids play in important biological functions such as transmission of genetic traits and protein synthesis has been elucidated, it has become increasingly important to understand the relationship between their structure and function. ing. One research method that is often used is to synthesize oligonucleotides having a desired base sequence and examine their effects on protein synthesis systems to understand the relationship between structure and function.
本発明者は、酵素的手段を用いる塩基配列のき
まつたオリゴリボヌクレオチドの簡便かつ収率の
よい調製方法を開発すべく鋭意検討した結果、本
発明に到達した。 The present inventor has arrived at the present invention as a result of intensive studies aimed at developing a simple and high-yield method for preparing oligoribonucleotides with a fixed base sequence using enzymatic means.
本発明の要旨は、アール・エヌ・エーリガーゼ
を触媒として用い、ジリボヌクレオシド5′，3′−
ジフオスフエートの5′−フオスフエートのヒドロ
キシル基をアルキル基でブロツク化したものと、
リボヌクレオチド5′，3′−ジフオスフエートとを
反応させることを特徴とするオリゴリボヌクレオ
チドの製造法に存する。 The gist of the present invention is to use R.N. eligase as a catalyst to produce diribonucleoside 5',3'-
5′-phosphonate diphosphonate whose hydroxyl group is blocked with an alkyl group,
The present invention relates to a method for producing oligoribonucleotides, which comprises reacting ribonucleotides with 5',3'-diphosphate.
本発明を詳細に説明するに、触媒として用いる
アール・エヌ・エーリガーゼ（以下において、こ
れをRNAリガーゼと記す）としては、ビオキミ
カ・エト・ビオフイジカ・アクタ第562巻149〜
161頁（1979年）に記載された方法に従い、ほぼ
リボヌクレアーゼが存在しない程度に精製したも
のが用いられる。すなわち、T4フアージを感染
された大腸菌を破砕し、その破砕液から、硫安沈
澱、カラムクロマトグラフイーなどにより分離精
製することによつてRNAリガーゼが得られる。 To explain the present invention in detail, RN Eligase (hereinafter referred to as RNA ligase) used as a catalyst is Biochimica Et Biofijica Acta Vol. 562, 149-
According to the method described on page 161 (1979), it is purified to the extent that almost no ribonuclease is present. That is, RNA ligase can be obtained by disrupting E. coli infected with T4 phage and separating and purifying the disrupted solution by ammonium sulfate precipitation, column chromatography, or the like.
一方原料第１成分として用いられるジリボヌク
レオシド5′，3′−ジフオスフエートのヒドロキシ
ル基をアルキル基でブロツク化したものとして
は、ジリボヌクレオシド5′，3′−ジフオスフエー
トの5′−フオスフオアルキルエステルまたは挙げ
られ、具体的には式CH3−pApAで表わされる
5′−Ｏ−ホスホリル−アデニリル（3′→5′）アデ
ノシンのメチルエステルが挙げられる。 On the other hand, 5'-phosphoalkyl ester of diribonucleoside 5',3'-diphosphate used as the first component of the raw material, in which the hydroxyl group of diribonucleoside 5',3'-diphosphate is blocked with an alkyl group, is or specifically represented by the formula CH 3 −pApA
Examples include methyl ester of 5'-O-phosphoryl-adenylyl (3'→5') adenosine.
また、第２成分のリボヌクレオチド5′，3′−ジ
フオスフエートとしては、pCpで表わされるシチ
ジン5′，3′−ジフオスフエート、pApで表わされ
るアデノシン5′，3′−ジフオスフエート、pUpで
表わされるウリジン5′，3′−ジフオスフエート、
pGpで表わされるグアノシン5′，3′−ジフオスフ
エート等が挙げられる。 The second component ribonucleotide 5',3'-diphosphate includes cytidine 5',3'-diphosphate represented by pCp, adenosine 5',3'-diphosphate represented by pAp, and uridine 5'-diphosphate represented by pUp. ′,3′-diphosphate,
Examples include guanosine 5',3'-diphosphate represented by pGp.
反応は、上記第１成分および第２成分を、
RNAリガーゼ、アデノシン三リン酸、MgCl2、
ジチオスレイトール、牛血清アルブミンなどを含
む緩衝液に加え、25〜45℃程度の温度に20分〜数
時間保持することによりおこなわれる。 In the reaction, the first component and the second component are
RNA ligase, adenosine triphosphate, MgCl2 ,
This is done by adding a buffer solution containing dithiothreitol, bovine serum albumin, etc., and maintaining it at a temperature of about 25 to 45°C for 20 minutes to several hours.
反応後、反応物をDEAE−セフアデツクス（セ
フアデツクスは商標）のようなゲル過剤のカラ
ムに加え、カラムクロマトグラフイーをおこなう
ことにより、容易に反応物のオリゴリボヌクレオ
チドを得ることができる。 After the reaction, the reaction product can be easily obtained as an oligoribonucleotide by adding the reaction product to a gel filter column such as DEAE-Sephadex (Sephadex is a trademark) and performing column chromatography.
以上説明した本発明によれば、ジリボヌクレオ
シド5′，3′−ジフオスフエートの5′−フオスフエ
ートのヒドロキシル基をブロツク化することによ
り、収率よくオリゴリボヌクレオチドを得ること
ができる。 According to the present invention as described above, oligoribonucleotides can be obtained in good yield by blocking the hydroxyl group of the 5'-phosphate of diribonucleoside 5',3'-diphosphate.
以下、本発明を実施例に従つてさらに詳細に説
明する。 Hereinafter, the present invention will be explained in more detail with reference to Examples.
実施例 １
(1) 第１成分の調製
ジヤーナル・オブ・アメリカン・ケミカル・
ソサイアテイ第81巻4657頁記載の方法に従い、
次のようにしてCH3−pApAを調製した。Example 1 (1) Preparation of first component Journal of American Chemical
According to the method described in Society Vol. 81, page 4657,
CH3 -pApA was prepared as follows.
pApAピリジニウム塩（ポリＡを蚕のヌクレ
アーゼで部分分解したもの）6.8mgにメタノー
ル1.5ml、トリエチルアミン0.05mlおよびジシ
クロヘキシルカルボジイミドの1Mピリジン溶
液0.25mlを加え、密栓をして24〜48時間室温で
反応させた。収率86.9％でCH3−pApAを得た。 Add 1.5 ml of methanol, 0.05 ml of triethylamine, and 0.25 ml of a 1M pyridine solution of dicyclohexylcarbodiimide to 6.8 mg of pApA pyridinium salt (polyA partially decomposed with silkworm nuclease), cap tightly, and react at room temperature for 24 to 48 hours. Ta. CH3 -pApA was obtained with a yield of 86.9%.
(2) 反応
(1)で得られたCH3−pApA0.1ｍＭ、pCp0.1
ｍＭアデノシン三リン酸0.5ｍＭ、MgCl220ｍ
Ｍ、ジチオスレイトール3.3ｍＭ、牛血清アル
ブミン10μｇ／ml、50ｍＭトリス塩酸緩衝液PH
8.1および66単位／mlT4RNAリガーゼ（T4フ
アージ感染大腸菌から調製したもの）を含む反
応液を37℃で60分間保持し、得られた反応液を
DEAEセフアデツクス（フアルマシア社製のゲ
ル過剤、セフアデツクスは商標）A25のカラ
ムに加え、0M→0.4Mの線状濃度勾配の重炭酸
アンモニウムを含むトリス塩酸緩衝液PH8.1で
溶出をおこない、0.3Mで溶出してくる画分か
ら、収率53％でCH3−pApApCpで表わされる
5′−Ｏ−ホスホリル−アデニリル（3′→5′）ア
デニリル（3′→5′）シチジル（3′）酸のメチル
エステルが得られた。(2) CH 3 -pApA0.1mM, pCp0.1 obtained in reaction (1)
mM adenosine triphosphate 0.5mM, MgCl2 20mM
M, dithiothreitol 3.3mM, bovine serum albumin 10μg/ml, 50mM Tris-HCl buffer PH
The reaction solution containing 8.1 and 66 units/ml T4 RNA ligase (prepared from T4 phage-infected E. coli) was kept at 37°C for 60 minutes, and the resulting reaction solution was
Add to DEAE Cephadex (gelling agent manufactured by Pharmacia, Cephadec is a trademark) A25 column and elute with Tris-HCl buffer pH 8.1 containing ammonium bicarbonate with a linear concentration gradient of 0M → 0.4M. From the fraction eluted at
The methyl ester of 5'-O-phosphoryl-adenylyl (3'→5') adenylyl (3'→5') cytidyl (3') acid was obtained.
比較例 １
CH3−pApAのかわりにpApAを用いたほかは
実施例１と同様にして反応させたところ、収率は
15％であつた。Comparative Example 1 The reaction was carried out in the same manner as in Example 1 except that pApA was used instead of CH 3 -pApA, and the yield was
It was 15%.
Claims (1)
い、ジリボヌクレオシド5′，3′−ジフオスフエー
トの5′−フオスフエートのヒドロキシル基をアル
キル基でブロツクしたものと、リボヌクレオチド
5′，3′−ジフオスフエートとを反応させることを
特徴とするオリゴリボヌクレオチドの製造法。1 Using RN eligase as a catalyst, diribonucleoside 5',3'-diphosphate with the hydroxyl group of 5'-phosphate blocked with an alkyl group, and ribonucleotide
1. A method for producing oligoribonucleotides, which comprises reacting with 5',3'-diphosphate.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP4709680A JPS56144095A (en) | 1980-04-10 | 1980-04-10 | Preparation of oligoribonucleotide |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP4709680A JPS56144095A (en) | 1980-04-10 | 1980-04-10 | Preparation of oligoribonucleotide |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS56144095A JPS56144095A (en) | 1981-11-10 |
| JPH0226958B2 true JPH0226958B2 (en) | 1990-06-13 |
Family
ID=12765648
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP4709680A Granted JPS56144095A (en) | 1980-04-10 | 1980-04-10 | Preparation of oligoribonucleotide |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS56144095A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH09159926A (en) * | 1995-12-14 | 1997-06-20 | Nec Corp | Wide-angle periscopic device |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1983002626A1 (en) * | 1982-02-01 | 1983-08-04 | Innovax Lab Ltd | Method for production of predetermined polyribonucleotides |
-
1980
- 1980-04-10 JP JP4709680A patent/JPS56144095A/en active Granted
Non-Patent Citations (1)
| Title |
|---|
| BIOCHEMISTRY=1978 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH09159926A (en) * | 1995-12-14 | 1997-06-20 | Nec Corp | Wide-angle periscopic device |
Also Published As
| Publication number | Publication date |
|---|---|
| JPS56144095A (en) | 1981-11-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU710074B2 (en) | Novel method of preparation of known and novel 2'-modified nucleosides by intramolecular nucleophilic displacement | |
| US6008400A (en) | Orthoester reagents for use as protecting groups in oligonucleotide synthesis | |
| US5869696A (en) | Universal solid supports and methods for their use | |
| US6921818B2 (en) | Purification of oligomers | |
| US5856464A (en) | Selective capping solution phase oligonucleotide synthesis | |
| JPH0631305B2 (en) | Nucleoside derivative | |
| JPH03505452A (en) | Sulfur-containing oligonucleotide analogs | |
| JP2005089441A (en) | Manufacturing method of highly stereoregular phosphorus atom-modified nucleotide analogue | |
| WO2000018778A9 (en) | Synthesis of codon randomized nucleic acids | |
| EP1272501B1 (en) | Process for the preparation of phosphorothioate triesters | |
| Ogilvie et al. | The synthesis of oligoribonucleotides VI. The synthesis of a hexadecamer by a block condensation approach | |
| JPH0226958B2 (en) | ||
| CA1339644C (en) | Method of preparing beta-2',2'-difluoronucleosides | |
| KR20040014479A (en) | Building blocks for the solution phase synthesis of oligonucleotides | |
| JPWO2005070946A1 (en) | Solution phase synthesis of ribonucleic acid compounds and oligonucleic acid compounds | |
| Bogdan et al. | The synthesis of allyl-and allyloxycarbonyl-protected RNA phosphoramidites. Useful reagents for solid-phase synthesis of RNAs with base-labile modifications | |
| JPH0371109B2 (en) | ||
| Reese | Protection of 2′‐hydroxy functions of ribonucleosides | |
| WO1996018638A2 (en) | 2'-o-derivatized pyrimidine ribonucleosides and methods of production | |
| Walker | THE SYNTHESIS OF OLIGORIBONUCLEOTIDES AND THE SYNTHESIS AND BIOLOGICAL ACTIVITY OF ALKYLATED NUCLEIC ACID COMPONENTS. | |
| CA2078256A1 (en) | Synthesis of sulfide-linked di-or oligonucleotide analogs and incorporation into antisense dna or rna | |
| JPH0134238B2 (en) | ||
| JP2575372B2 (en) | Anticancer agent | |
| Saraya et al. | A facile and general tandem oligonucleotide synthesis methodology for DNA and RNA | |
| JP3006009B2 (en) | Method for producing nucleoside derivative by selective hydrolysis |